Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 362 | 89 | 270 |
| Samples | 347 | 89 | 255 |
| Peptides | 229 | 38 | 196 |
Function
IL2RB · Interleukin 2 receptor subunit beta
The interleukin 2 receptor, which is involved in T cell-mediated immune responses, is present in 3 forms with respect to ability to bind interleukin 2. The low affinity form is a monomer of the alpha subunit and is not involved in signal transduction. The intermediate affinity form consists of an alpha/beta subunit heterodimer, while the high affinity form consists of an alpha/beta/gamma subunit heterotrimer. Both the intermediate and high affinity forms of the receptor are involved in receptor-mediated endocytosis and transduction of mitogenic signals from interleukin 2. The protein encoded by this gene represents the beta subunit and is a type I membrane protein. The use of alternative promoters results in multiple transcript variants encoding the same protein. The protein is primarily expressed in the hematopoietic system. The use by some variants of an alternate promoter in an upstream long terminal repeat (LTR) results in placenta-specific expression. [provided by RefSeq, Sep 2016].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000216223 | P14784 | 361 | 228 |
| ENST00000703410 | A0A8W6ANL8* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 228 amino-acid changes on canonical ENST00000216223 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL2RB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL2RB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Melanoma | 14/210 7% | 66/1899 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Other Sarcomas | 3/69 4% | 10/699 1% |
| Endometrial Carcinoma | 0/42 0% | 11/612 2% |
| Non-Small Cell Lung Carcinoma | 14/304 5% | 13/1390 1% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 9/810 1% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Other Solid Cancers | 0/94 0% | 23/1515 2% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Colorectal Carcinoma | 7/143 5% | 21/3239 1% |
| Neuroendocrine Tumour | 4/154 3% | 2/577 0% |
| Hepatocellular Carcinoma | 5/46 11% | 13/2210 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 11/1592 1% |
| Head and Neck Carcinoma | 4/85 5% | 8/1574 1% |
| Cervical Carcinoma | 2/35 6% | 1/422 0% |
| Bladder Carcinoma | 0/58 0% | 6/956 1% |
| Gastric Carcinoma | 1/74 1% | 9/1809 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Glioma | 2/52 4% | 6/2127 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
Mutation Distribution
Where IL2RB is mutated · all tissues, split by cell line vs tissue
How many mutations in IL2RB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 362 mutations in IL2RB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|